| Literature DB >> 32316123 |
Asem Sanjit Singh1, Binaya Bhusan Nayak1, Sanath H Kumar1.
Abstract
In this study, fresh seafood in retail markets was investigated for the antibiotic susceptibility patterns of the faecal indicator Escherichia coli and distribution of important β-lactamase encoding genes. E. coli were isolated from 50 (37 fish and 13 shellfish) fresh seafood samples and studied with respect to the phenotypic and genotypic characters of antibiotic resistance. Of 475 E. coli isolates from fresh seafood, 71.58% exhibited extended-spectrum β-lactamase (ESBL)-positive phenotypes. A high percentage of isolates were resistant to indicator cephalosporins cefotaxime (95%), cefpodoxime (90.88%) and ceftazidime (90.29%). Relatively higher susceptibilities were recorded against imipenem (74.41%), cefoxitin (66.76%) and meropenem (51.18%). The multiple antibiotic resistance (MAR) index of 97.35% of the isolates was above 0.18. The ESBL genes blaCTX-M, blaSHV and blaTEM were detected in 62.37%, 23.35% and 2.6% of E. coli isolates, respectively. The ESBL-producing isolates also harboured the metallo-β-lactamase-encoding genes blaOXA (7.06%), blaNDM (4.42%) and blaVIM (0.88%). This study highlights the risk of dissemination of multidrug resistant E. coli in seafood consumer communities and also the need to improve the hygiene of the coastal waters, landing centres and the retail markets.Entities:
Keywords: India; MAR index; MBL; PCR; beta lactamase; disc diffusion; seafood
Year: 2020 PMID: 32316123 PMCID: PMC7356741 DOI: 10.3390/vetsci7020046
Source DB: PubMed Journal: Vet Sci ISSN: 2306-7381
Sample-wise distribution of Escherichia coli and ESBL+ isolates.
| Sl. No. | Samples | No. Analysed | No. of | No. (%) ESBL+
|
|---|---|---|---|---|
| Finfish | ||||
| 1. |
| 5 | 32 | 24 (75) |
| 2. |
| 5 | 29 | 29 (100) |
| 3. |
| 3 | 19 | 19 (100) |
| 4. |
| 2 | 15 | 15 (100) |
| 5. |
| 2 | 22 | 14 (64.28) |
| 6. |
| 2 | 24 | 13 (53.84) |
| 7. |
| 3 | 45 | 32 (71.87) |
| 8. |
| 4 | 42 | 35 (82.85) |
| 9. |
| 2 | 21 | 12 (58.33) |
| 10. |
| 2 | 19 | 13 (69.23) |
| 11. |
| 2 | 25 | 25 (100) |
| 12. |
| 3 | 13 | 13 (100) |
| 13. |
| 2 | 19 | 17 (88.23) |
| Shellfish | ||||
| 14. |
| 5 | 56 | 27 (48.21) |
| 15. |
| 3 | 41 | 19 (73.68) |
| 16. |
| 3 | 26 | 18 (44.44) |
| 17. |
| 2 | 27 | 15 (26.66) |
| Total | 50 | 475 | 340 (71.58) |
Antibiotic susceptibility profiles of ESBL+ E. coli (n = 340) isolated in this study.
| Antibiotic Tested | No. (%) Resistant | No. (%) Intermediate Resistant | No. (%) Susceptible |
|---|---|---|---|
| Cefoxitin (CX) 30 mcg | 66 (19.41%) | 47 (13.82%) | 227 (66.76%) |
| Cefotaxime (CTX) 30 mcg | 323 (95%) | 12 (3.53%) | 5 (1.47%) |
| Ceftazidime (CAZ) 30mcg | 307 (90.29%) | 26 (7.65%) | 7 (2.05%) |
| Cefpodoxime (CPD) 10 mcg | 309 (90.88%) | 17 (5.0%) | 14 (4.11%) |
| Imipenem (IPM) 10mcg | 31 (9.11%) | 56 (16.47%) | 253 (74.41%) |
| Ertapenem (ETP) 10 mcg | 107 (31.47%) | 81 (23.82%) | 152 (44.71%) |
| Meropenem (MRP) 10 mcg | 87 (25.58%) | 79 (23.24%) | 174 (51.18%) |
| Ciprofloxacin (CIP) 5mcg | 152 (44.71%) | 43 (12.65%) | 145 (42.65%) |
| Aztreonam (AT) 30 mcg | 219 (64.41%) | 57 (16.76%) | 64 (18.82%) |
| Amoxyclav (AMC) 30 mcg | 127 (37.35%) | 83 (24.41%) | 130 (38.24%) |
| Piperacillin/Taz 100/10mcg | 114 (33.53%) | 95 (27.94%) | 131 (38.53%) |
Distribution of β-lactamase genes in Escherichia coli isolated in this study.
| Samples Analysed (No.) | No. of | No. (%) ESBL+ | No. (%) CTX-M+ | No. (%) SHV+ | No. (%) TEM+ | No. (%) OXA+ | No. (%) VIM+ | No. (%) NDM+ |
|---|---|---|---|---|---|---|---|---|
|
| 32 | 24 (75) | 22 (91.66) | 3 (12.5) | 3 (12.5) | 3 (12.5) | 1 (3.13) | 3 (9.38) |
|
| 29 | 29 (100) | 18 (62.06) | 1 (3.45) | - | 1 (3.45) | 1 (3.45) | - |
|
| 19 | 19 (100) | 17 (89.47) | 3 (15.79) | 1(5.26) | 1(5.26) | 1 (5.26) | 3 (15.78) |
|
| 15 | 15 (100) | 13 (86.66) | - | 1 (6.67) | 1(6.67) | - | 1 (6.66) |
|
| 22 | 14 (64.28) | 5 (35.71) | 5 (35.71) | - | - | - | 2 (9.09) |
|
| 24 | 13 (53.84) | 5 (38.46) | 2 (15.38) | - | - | - | - |
|
| 45 | 32 (71.87) | 25 (78.13) | 7 (21.86) | 1 (3.13) | 7 (21.88) | - | 3 (6.66) |
|
| 42 | 35 (82.85) | 27 (77.14) | 7 (20) | 1 (2.86) | 4 (11.43) | - | 1 (2.38) |
|
| 21 | 12 (58.33) | 5 (41.67) | 9 (75) | - | - | - | 2 (9.52) |
|
| 19 | 13 (69.23) | 3 (23.08) | 7 (53.85) | - | - | - | - |
|
| 25 | 25 (100) | 9 (36) | 11 (44) | - | 1 (4) | - | 2 (8) |
|
| 13 | 13 (100) | 4 (30.77) | - | - | 1 (7.69) | - | - |
|
| 19 | 17 (88.23) | 13 (76.47) | 9 (52.94) | - | 2 (11.76) | - | - |
|
| 27 | 27 (100) | 23 (85.19) | 12 (44.44) | - | 1 (3.70) | - | 2 (7.4) |
|
| 26 | 19 (73.68) | 11 (57.89) | 2 (10.53) | 2 (10.53) | 1 (5.26) | - | - |
|
| 41 | 18 (44.44) | 9 (50) | 1 (5.56) | - | 1 (5.56) | - | 2 (4.88) |
|
| 56 | 15 (26.66) | 3 (20) | - | - | - | - | - |
|
|
|
|
|
|
|
|
|
|
Figure 1Antibiotic resistance profiles of E. coli harbouring blaCTX-M (n = 212; fish 166, shellfish 46) (A), blaSHV (n = 79; fish 64, shellfish 15) (B) and blaTEM (n = 9; fish 7, shellfish 2) (C). R = resistant, I = Intermediate resistant and S = susceptible.
Figure 2Antibiotic resistance profiles of Escherichia coli isolates harbouring blaOXA (n = 24; fish 21, shellfish 3) (A), blaNDM (n = 21, fish 17, shellfish 4 (B) and blaVIM (n = 3, fish 3, shellfish 0) (C) genes. R = resistant, I = Intermediate resistant and S = susceptible.
Multiple antibiotic resistance (MAR) indices of Escherichia coli.
| No. of Antibiotic | MAR Index | No. (%) of Isolates |
|---|---|---|
| 1 | 0.09 | 9 (2.64) |
| 2 | 0.18 | 7 (2.06) |
| 3 | 0.27 | 71 (20.88) |
| 4 | 0.36 | 11 (3.24) |
| 5 | 0.45 | 102 (30) |
| 6 | 0.55 | 13 (3.82) |
| 7 | 0.64 | 53 (15.59) |
| 9 | 0.82 | 41 (12.06) |
| 11 | 1.00 | 21 (6.18) |
Characteristics of the E. coli isolates exhibiting the highest resistance phenotypes from each sample type.
| Isolate No. | Source | Resistance Genotype | Antibiotic Resistance Profile | Antibiotic to which Susceptible |
|---|---|---|---|---|
| EC21 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC123 |
| CX, CTX, CAZ, CPD, MRP, AT | IPM, CIP, ETP, AMC, PIT | |
| EC31 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC91 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC81 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC13 |
| CX, CTX, CAZ, CPD, CIP, AT | IPM, MRP, ETP, AMC, PIT | |
| EC221 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC201 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC303 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC48 |
| CX, CTX, CAZ, CPD, CIP, AT, AMC, PIT | IPM, ETP, MRP | |
| EC51 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC253 |
| CX, CTX, CAZ, CPD, CIP, AT, ETP | IPM, MRP, AMC, PIT | |
| EC271 |
| CX, CTX, CAZ, CPD, CIP, AT, PIT | IPM, ETP, MRP, AMC | |
| EC281 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC253 |
| CX, CTX, CAZ, CPD, IPM, CIP, AT, AMC, PIT | IPM, AMC, PIT | |
| EC305 |
| CX, CTX, CAZ, CPD, IPM, ETP, MRP, CIP, AT, AMC, PIT | CL | |
| EC131 |
|
| CX, CTX, CAZ, CPD, CIP | IPM, ETP, MRP, AMC, PIT |